Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT02041130
Registration number
NCT02041130
Ethics application status
Date submitted
28/10/2013
Date registered
20/01/2014
Date last updated
16/01/2015
Titles & IDs
Public title
Renal Denervation in Heart Failure Patients With Preserved Ejection Fraction (RESPECT-HF)
Query!
Scientific title
Renal Sympathectomy in Heart Failure (the RESPECT-HF Study) - a Study of Renal Denervation for Heart Failure With Preserved Ejection Fraction
Query!
Secondary ID [1]
0
0
DSRB: 2013/00457
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
RESPECT-HF
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Heart Failure
0
0
Query!
Condition category
Condition code
Cardiovascular
0
0
0
0
Query!
Coronary heart disease
Query!
Cardiovascular
0
0
0
0
Query!
Other cardiovascular diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Devices - Renal Denervation
Experimental: Renal Denervation and standard medical management - Renal Denervation (RDN) is a simple catheter procedure removing excess nerve signals to and from the kidneys. The renal denervation system consists of a small steerable treatment catheter and an automatically-controlled treatment delivery generator.
A guiding catheter is inserted through a tiny incision in the groin into the femoral artery to direct the treatment catheter to the renal arteries. The treatment catheter delivers high -frequency radio waves, called radiofrequency wavees, to 4-6 locations within each of the two renal arteries. the energy delivered is about 8 watts and aims to disrupt the nerves and lower blood pressure over a period of months. The procedure takes 40-60 minutes.
No Intervention: Contorl and Standard Medical Management - Continued medical management will comprise management of all cardiovascular risk factors (hypertension, diabetes, dyslipidaemia) in accord with international guidelines. Lifestyle and dietary counselling will also be part of the patient management. As there is no established evidence-based pharmacotherapy for HFPEF per se, therapy aimed at HF specifically will adopt treatments recommended for HFREF with prescription of diuretic, ACE inhibitor/ARB, beta blocker and mineralocorticoid antagonist accordingly.
Treatment: Devices: Renal Denervation
Query!
Intervention code [1]
0
0
Treatment: Devices
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Compare the changes in left atrial volume index (LAVi) and/or left ventricular mass index (LVMi) on cardiac magnetic resonance imaging (cMRI) between baseline and 6 months
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
baseline, 6 months
Query!
Secondary outcome [1]
0
0
Compare the changes in exercise capacity and functional status as assessed by maximal oxygen consumption (VO2max) on cardiopulmonary exercise testing and by 6-minute walk test between baseline and 6 months
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
baseline, 6 months
Query!
Secondary outcome [2]
0
0
Compare the changes in chocardiographic grade of diastolic dysfunction as assessed by Tissue Doppler E/e', (a non-invasive estimate of left atrial filling pressure).
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
baseline, 6 months
Query!
Secondary outcome [3]
0
0
Compare the changes in biomarkers of cardiac load and interstitial fibrosis as assessed by plasma assays of relevant biomarkers
Query!
Assessment method [3]
0
0
The biomarkers of cardiac load and interstitial fibrosis as assessed by plasma assays of markers of ventricular and atrial haemodynamic load, other neurohormones contributing to HF pathophysiology, cytokine markers of inflammation and remodelling, markers of cardiac fibrosis, a marker of cardiomyocyte loss.
Query!
Timepoint [3]
0
0
baseline, 6 months
Query!
Secondary outcome [4]
0
0
Compare the changes in ventricular-vascular function as evaluated by echocardiographic measures of arterial elastance, Left Ventricular (LV) end-systolic elastance, LV filling pressure, and LV diastolic stiffness between baseline and 6 months
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
baseline, 6 months
Query!
Secondary outcome [5]
0
0
Compare the changes of Quality of life as assessed by the Minnesota Living with Heart Failure between baseline and 6 months.
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
baseline, 6 months
Query!
Secondary outcome [6]
0
0
Compare the difference in composite end-point of death or hospitalization with Heart Failure between control arm and treatment arm
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
baseline, 6 months
Query!
Eligibility
Key inclusion criteria
1. Patients with HFPEF (based upon ESC diagnostic criteria9)
1. Symptoms and signs of heart failure; NYHA Class II or higher
2. Left ventricular ejection fraction 50% or greater on echocardiography
3. Echocardiographic evidence of left ventricular diastolic dysfunction
(echo-Doppler E/e' > 15 )AND/OR plasma NTproBNP > 220pg/ml.
2. Episode of acute decompensation (ADHF)
3. Patients with and without background hypertension may be recruited. In the case of
patients with background hypertension (ie history of fulfilling the diagnostic WHO
criteria for hypertension: SBP > 140 mmHg and/or DBP > 90 mmHg) those with both
controlled (<140/90mmHg by 24 hour ambulatory BP) and inadequately controlled BP (on 3
anti-hypertensive drugs including a diuretic) can be recruited.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1. Known secondary cause of hypertension
2. Renal artery stenosis >30% or anatomy otherwise unsuitable for RDN.
3. Heart failure with reduced LV ejection fraction (LVEF < 50%).
4. Estimated glomerular filtration rate (eGFR) of < 30mL/min/1.73m2 (MDRD calculation).
5. Systolic blood pressure < 105mmHg.
6. Implanted pacemaker, prosthetic heart valve or other precluding cMR scanning.
7. Medical condition adversely affecting safety and/or effectiveness of the participant
(including peripheral vascular disease, abdominal aortic aneurysm, thrombocytopenia or
atrial fibrillation).
8. Pregnant, nursing or planning to be pregnant.
9. Uncontrolled atrial fibrillation, ie with heart rate over 120 bpm
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Unknown status
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/10/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
1/12/2016
Query!
Actual
Query!
Sample size
Target
144
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Monash University - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
New Zealand
Query!
State/province [1]
0
0
Auckland
Query!
Country [2]
0
0
New Zealand
Query!
State/province [2]
0
0
Christchurch
Query!
Country [3]
0
0
New Zealand
Query!
State/province [3]
0
0
Wellington
Query!
Country [4]
0
0
Singapore
Query!
State/province [4]
0
0
Singapore
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
National University Hospital, Singapore
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Other
Query!
Name [1]
0
0
University of Otago
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Other collaborator category [2]
0
0
Other
Query!
Name [2]
0
0
Wellington Hospital
Query!
Address [2]
0
0
Query!
Country [2]
0
0
Query!
Other collaborator category [3]
0
0
Other
Query!
Name [3]
0
0
University of Auckland, New Zealand
Query!
Address [3]
0
0
Query!
Country [3]
0
0
Query!
Other collaborator category [4]
0
0
Other
Query!
Name [4]
0
0
Monash University
Query!
Address [4]
0
0
Query!
Country [4]
0
0
Query!
Other collaborator category [5]
0
0
Other
Query!
Name [5]
0
0
Tan Tock Seng Hospital
Query!
Address [5]
0
0
Query!
Country [5]
0
0
Query!
Other collaborator category [6]
0
0
Other
Query!
Name [6]
0
0
Changi General Hospital
Query!
Address [6]
0
0
Query!
Country [6]
0
0
Query!
Other collaborator category [7]
0
0
Other
Query!
Name [7]
0
0
Singapore Clinical Research Institute
Query!
Address [7]
0
0
Query!
Country [7]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Investigators will test a new approach to a form of heart failure (HF) with no current
treatment proven to reduce death rates or hospitalisations. Over a third of HF cases have
preserved ejection fraction (HFPEF) often on a background of high blood pressure (BP). These
"stiff" hearts pump strongly but fill inefficiently resulting in poor exercise capacity and
high death rates. Treatments that help when heart pumping action is poor are of no benefit in
HFPEF. Recently a simple catheter procedure removing excess nerve signals to and from the
kidneys ("renal denervation"; RDN) has been able to reduce BP in patients with high BP
resistant to multi-drug treatment. Through removing excess nervous drive to the kidneys,
heart and circulation this treatment has promise in HF. The investigators will compare
effects of RDN and standard medical treatment on heart function, exercise capacity and
quality of life in 144 patients with HFPEF
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT02041130
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Arthur Mark Richards, MBChB, MD (Distinction), PhD
Query!
Address
0
0
University of Otago, Christchurch
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Mark Richards Arthur, MBChB, MD (Distinction), PhD
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT02041130
Download to PDF